Page 20«..10..19202122..3040..»

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Posted: August 14, 2024 at 2:37 am

SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.

See the original post here:
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Posted in Global News Feed | Comments Off on BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Posted: August 14, 2024 at 2:37 am

- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 -

View original post here:
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Posted in Global News Feed | Comments Off on Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Posted: August 14, 2024 at 2:37 am

• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death• AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific T-cell response with ~66% of responses including both CD4+ and CD8+ T cells• Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall survival to preserve resources with updated data to be shared at upcoming medical meetings• AMPLIFY-7P Phase 2 randomized clinical trial anticipated to complete 135-patient enrollment in the fourth quarter of 2024• $43 million raised in 2024 funds Elicio into the second quarter of 2025

Link:
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Posted in Global News Feed | Comments Off on Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Lowell Farms Inc. Announces Unaudited Second Quarter 2024 Financial and Operational Results

Posted: August 14, 2024 at 2:37 am

SALINAS, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, announces unaudited revenue and operating results for the second quarter of 2024 (ended June 30, 2024). All figures stated are in US Dollars.

The rest is here:
Lowell Farms Inc. Announces Unaudited Second Quarter 2024 Financial and Operational Results

Posted in Global News Feed | Comments Off on Lowell Farms Inc. Announces Unaudited Second Quarter 2024 Financial and Operational Results

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Posted: August 14, 2024 at 2:37 am

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.

Go here to see the original:
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Posted: August 14, 2024 at 2:37 am

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended June 30, 2024, and reviewed recent business highlights.

The rest is here:
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Posted in Global News Feed | Comments Off on Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Posted: August 14, 2024 at 2:37 am

This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14.

See the original post here:
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Posted in Global News Feed | Comments Off on Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in…

Posted: August 14, 2024 at 2:37 am

INSIDE INFORMATION

See the original post:
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in...

Posted in Global News Feed | Comments Off on Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in…

Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update

Posted: August 14, 2024 at 2:36 am

See the original post:
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update

44,767 Orion Corporation A shares converted into B shares

Posted: August 14, 2024 at 2:36 am

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE14 AUGUST 2024 at 9.30 EEST

Follow this link:
44,767 Orion Corporation A shares converted into B shares

Posted in Global News Feed | Comments Off on 44,767 Orion Corporation A shares converted into B shares

Page 20«..10..19202122..3040..»